892 results on '"Winer E"'
Search Results
52. P515: LOWER-INTENSITY CPX-351 + VENETOCLAX FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY
53. Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB)
54. Erratum to “Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust”
55. Using theory to guide exploratory network analyses.
56. 1st International consensus guidelines for advanced breast cancer (ABC 1)
57. Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia
58. Subchance perception: Anxious, non-defensive individuals identify subliminally-presented positive words at below-chance levels
59. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer
60. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance)
61. Reward Devaluation: Dot-Probe Meta-Analytic Evidence of Avoidance of Positive Information in Depressed Persons
62. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust
63. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
64. A Network Approach to Understanding Narcissistic Grandiosity via the Narcissistic Admiration and Rivalry Questionnaire and the Narcissistic Personality Inventory.
65. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
66. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
67. A Network Approach to Understanding Narcissistic Grandiosity via the Narcissistic Admiration and Rivalry Questionnaire and the Narcissistic Personality Inventory
68. Examining rumination, devaluation of positivity, and depressive symptoms via community‐based network analysis
69. A Dark Web of Personality: Network Analyses of Dark Personality Features and Pathological Personality Traits
70. Adjuvant endocrine therapy for pre- and postmenopausal women
71. Signal Detection Theory
72. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer
73. Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery?
74. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
75. The impact of sharing results of a randomized breast cancer clinical trial with study participants
76. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)
77. Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB)
78. Signal Detection Theory
79. Negative affect interference and fear of happiness are independently associated with depressive symptoms
80. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
81. Attitudes of patients with metastatic breast cancer toward research biopsies
82. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer
83. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship
84. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
85. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)
86. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840
87. CMF revisited in the 21st century
88. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer
89. Distress tolerance and symptoms of depression: A review and integration of literatures.
90. Negative self-schemas and devaluation of positivity in depressed individuals: A moderated network analysis
91. The current status of temporal network analysis for clinical science: Considerations as the paradigm shifts?
92. 137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)
93. 141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer
94. Abstract ES7-1: Progression of Disease and End of life: How to Break Bad News
95. Conceptualizing anhedonias and implications for depression treatments
96. Use of simple sequence length polymorphisms for genetic characterization of rat inbred strains
97. Predictability of heterozygosity scores and polymorphism information content values for rat genetic markers
98. Menopausal-type symptoms in young breast cancer survivors
99. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy
100. Anhedonia and the Relationship Between Other Depressive Symptoms and Aggressive Behavior.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.